NeuroSearch neurology news
NeuroSearch said the State Prosecutor from the Office for Economic Crime filed preliminary charges alleging share price manipulation from a Feb. 3, 2010 announcement of top-line results from the Phase III MermaiHD trial that sent NeuroSearch shares soaring DKK83 (98%) to DKK168. The company reported that twice-daily Huntexil pridopidine met the primary endpoint of significantly improving voluntary motor function vs. placebo at week 26 in patients with Huntington's disease. However, on April 28, 2010, the company released a revised analysis that showed the dopamine stabilizer did not meet the primary endpoint sending shares falling DKK52 (30%) to DKK120. The company is denying the charges and is collaborating fully with the authorities to resolve the matter (see BioCentury, Feb. 8, 2010 & May 3, 2010). ...